Industry

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) announced today that the first patient has been dosed in the global HERTHENA-Lung02 phase 3 trial evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus platinum-based chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with disease progression following … [Read more…]

— Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets — — Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB), a clinical-stage … [Read more…]

 Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company … [Read more…]

MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy Global SAFFRON Phase III trial evaluating this combination is underway WILMINGTON, Del.–(BUSINESS WIRE)–Preliminary results from the SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an objective response rate (ORR) of 49% (95% confidence interval … [Read more…]

Company Receives FDA Clearance of ALLY™ Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, … [Read more…]

EL DORADO HILLS, Calif.–(BUSINESS WIRE)–#O2Investment–Frontier Dental Lab Group (“Frontier” or “FDL Group”) (www.frontierdentallabgroup.com), a leading dental laboratory platform, announced today that it has partnered with and made an investment in D&S Dental Laboratory, Inc. (“D&S”) (https://dnsdental.com/), a full-service dental laboratory based in Waunakee, WI. Brent West, President of FDL Group, commented, “D&S has an extremely … [Read more…]

POTOMAC, Md.–(BUSINESS WIRE)–#IGC–India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company’s 2023 fiscal year. The highlights for the quarter are: The Company has submitted a protocol to the U.S. Food and Drug Administration … [Read more…]

The Company identifies critical milestones required to commence clinical trial programme LONDON–(BUSINESS WIRE)–SpectrumX, a UK-based healthcare and pharmaceutical company, is pleased to announce that is has a date for a scientific advice meeting with the UK Medicines and Healthcare products Regulatory Agency (MHRA) to discuss its human clinical trial programme. SpectrumX has confirmed the scientific … [Read more…]

Research also shows that cohort will turn to tech to battle loneliness and find support, disrupting common perception that it’s a negative influence on youth mental health REDWOOD CITY, Calif.–(BUSINESS WIRE)–New research from Telosity by Vinaj Ventures, the leader in the youth mental health investor space, indicates that school is the top trigger for depression … [Read more…]

VANCOUVER, British Columbia–(BUSINESS WIRE)–#education–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO), one of the largest publicly listed US based ketamine wellness clinics, is pleased to report continued expansion of service lines offering an online vitamin supplement line, an online global curriculum, and an onsite and virtual training program … [Read more…]